Back

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Read More

Back

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Read More

Back

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Read More